The offering, developed in collaboration with Beluga Health, is slated for commercial rollout in late 2026. It targets a shifting market where employers and health plans are moving away from broad, unrestricted coverage toward more controlled, clinically managed models. According to industry data, while many employers currently cover GLP-1 medications for weight management, a significant number are re-evaluating their commitments, creating a demand for more sustainable, outcome-focused approaches.

By consolidating digital engagement, connected monitoring, and clinical oversight under one roof, DarioHealth plans to address the disconnect often found when patients manage prescriptions and chronic conditions through separate providers. The program will be accessible through three primary channels: the company’s direct-to-consumer MyDario Shop, health plan marketplaces, and employer-sponsored B2B2C programs. Company leadership emphasizes that clinical eligibility will remain strictly tied to professional medical review, ensuring that prescriptions are issued only when clinically appropriate according to FDA labeling and evidence-based guidelines.